The in vitro antifungal activity of the dithiocarbamate organotin complexes [Sn{S2CN(CH2)4}2Cl2] (1), [Sn{S2CN(CH2)4}2Ph2] (2), [Sn{S2CN(CH2)4}Ph3] (3), [Sn{S2CN(CH2)4}2n‐Bu2] (4), [Sn{S2CN(CH2)4}Cy3] {Cy = cyclohexyl} (5), [Sn{S2CN(C2H5)2}2Cl2] (6), [Sn{S2CN(C2H5)2}2Ph2] (7), [Sn{S2CN(C2H5)2}Ph3] (8), [Sn{S2CN(C2H5)2}3Ph] (9) and [Sn{S2CN(C2H5)2}Cy3] (10) has been screened against Candida albicans (ATCC 18804), Candida tropicalis (ATCC 750) and resistant Candida albicans collected from HIV‐positive Brazilian patients with oral candidiasis. All compounds exhibited antifungal activities and complexes 3 and 8 displayed the best results. We have investigated the effect of compounds 1–10 on the cellular activity of the yeast cultures. Changes in mitochondrial function have not been detected. However, all drugs reduced ergosterol biosynthesis. Preliminary studies on DNA integrity indicated that the compounds do not cause gross damage to yeast DNA. The data suggest that these compounds share some mechanisms of action on cell membranes similar to that of polyene but not with azole drugs, normally used in Candida infections.
No takes yet. Share an insight, caveat, or question.
Menezes et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: